Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 15/20 | 1.00 |
| ▸ | CCND1 | P24385 | 14/20 | 1.00 |
| ▸ | CDK2 | P24941 | 12/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 11/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 9/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 4/20 | 1.00 |
| ▸ | NUAK1 | O60285 | 4/20 | 1.00 |
| ▸ | CDK1 | P06493 | 3/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 2/20 | 1.00 |
| ▸ | MARK3 | P27448 | 2/20 | 1.00 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 1.00 |
| ▸ | MARK4 | Q96L34 | 2/20 | 1.00 |
| ▸ | NUAK2 | Q9H093 | 2/20 | 1.00 |
| ▸ | MARK1 | Q9P0L2 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | CDK7 | P50613 | 2/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 1.00 |
| ▸ | PRKAB2 | O43741 | 1/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Narazaciclib SCHEMBL30418763 | 1.00 | CDK4 (1.00) | CDK4CCND1CDK2CCNA2FGFR1 | |
| Narazaciclib SCHEMBL14955407 | 0.99 | CDK4 (0.98) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL14955943 | 0.99 | CDK4 (0.98) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL14954855 | 0.98 | CDK4 (0.97) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL14955588 | 0.96 | CDK4 (0.93) | CDK4CCND1CDK2CCNA2FGFR1 | |
| Narazaciclib SCHEMBL26685640 | 0.96 | CDK4 (0.92) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL24618846 | 0.96 | CDK4 (0.92) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL22164862 | 0.94 | CDK4 (0.89) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL22860493 | 0.93 | CDK4 (0.87) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL22860695 | 0.93 | CDK4 (0.87) | CDK4CCND1CDK2CCNA2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 374 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075701-A | Use of NUAK A2 inhibitor in preparation of medicines for preventing or/and treating pulmonary fibrosis | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026101937-A1 | COMPOSITIONS COMPRISING (Z)-ENDOXIFEN AND A CDK4/6 INHIBITOR AND METHODS OF USE THEREOF | ATOSSA THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-12599562-B2 | Nanocrystal microparticles of poorly soluble drugs and methods of production and use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2026-04-14 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| EP-4704841-A1 | IMLUNESTRANT OR SALTS THEREOF FOR USE IN TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM (CNS) METASTASES IN SUBJECTS HAVING ER+ BREAST CANCER | Eli Lilly and Company (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250332145-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2025-10-30 | — | — | US | claimed |
| US-20250295693-A1 | HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS) | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2025-09-25 | — | — | US | claimed |
| US-12383529-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | claimed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| EP-2880448-B1 | HUMAN PAPILLOMA VIRUS AS PREDICTOR OF CANCER PROGNOSIS | FOUND MEDICINE INC (US) | 2022-06-29 | — | — | EP | claimed |
| US-20220168273-A1 | Pharmaceutical Combination for the Treatment of Cancer | Piramal Enterprises Limited (IN) | 2022-06-02 | — | — | US | claimed |
| WO-2022103834-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER | SYNDEVRX, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| US-11234963-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2022-02-01 | — | — | US | claimed |
| US-8987267-B2 | 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders | Temple University—Of the Commonwealth System of Higher Education (US) | 2015-03-24 | — | — | US | claimed |
| EP-2600719-B1 | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDINE-6-CARBONITRILES AND USES THEREOF | UNIV TEMPLE (US) | 2014-10-08 | — | — | EP | claimed |
| US-20130131058-A1 | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D] PYRIMIDINE-6-CARBONITRILES AND USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2013-05-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599562-B2 | Nanocrystal microparticles of poorly soluble drugs and methods of production and use thereof | CDK4, CDK5, CDK6 | CDK4 1/4885CCND1 18/4885CDK2 7/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | CDK4 102/4885CCND1 22/4885CDK2 24/4885 |
| US-20130131058-A1 | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D] PYRIMIDINE-6-CARBONITRILES AND USES THEREOF | CDK7, CDK2, CDK8 | CDK4 11/4885CCND1 99/4885CDK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.